Myriad
Myriad Genetics, MD Anderson Partner to Study Clinical Utility of MRD Assay
Under the five-year agreement, the partners will assess the clinical utility of Myriad's Precise MRD test in breast, gastrointestinal, genitourinary, and gynecological cancers.
Data from Myriad Genetics offered early validation evidence for an expanded version of its commercial test, as well as a look into clinical impact via claims data.
Updated NCCN Guidelines Adjust Ratings for Prostate Cancer Genetic Tests
The newest version ups its endorsement of somatic genomic testing to "recommended" for advanced cancers and shifts its recommendations on early-stage risk assays.
Illumina to Incorporate Myriad's Genomic Instability Score Into Updated TSO 500 Cancer Assay
GIS measures DNA repair defects via loss of heterozygosity, large-scale state transition, and telomere allele imbalance.
BRCA1/2 Mutations Aren't Equal: Researchers Push for Reduced Penetrance Pathogenic Variant Category
Premium
Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater recognition of such variants.